MX2015010428A - Anticuerpos anti-her2 altamente galactosilados y sus usos. - Google Patents
Anticuerpos anti-her2 altamente galactosilados y sus usos.Info
- Publication number
- MX2015010428A MX2015010428A MX2015010428A MX2015010428A MX2015010428A MX 2015010428 A MX2015010428 A MX 2015010428A MX 2015010428 A MX2015010428 A MX 2015010428A MX 2015010428 A MX2015010428 A MX 2015010428A MX 2015010428 A MX2015010428 A MX 2015010428A
- Authority
- MX
- Mexico
- Prior art keywords
- her2 antibodies
- highly galactosylated
- galactosylated anti
- disclosure relates
- highly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764488P | 2013-02-13 | 2013-02-13 | |
| PCT/IB2014/000711 WO2014125377A2 (en) | 2013-02-13 | 2014-02-13 | Highly galactosylated anti-her2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010428A true MX2015010428A (es) | 2016-04-13 |
Family
ID=50980322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010428A MX2015010428A (es) | 2013-02-13 | 2014-02-13 | Anticuerpos anti-her2 altamente galactosilados y sus usos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150368357A1 (https=) |
| EP (1) | EP2956485A2 (https=) |
| JP (2) | JP2016509019A (https=) |
| KR (1) | KR20160003634A (https=) |
| CN (1) | CN105308071A (https=) |
| AR (1) | AR094781A1 (https=) |
| AU (1) | AU2014217564B2 (https=) |
| BR (1) | BR112015019343A2 (https=) |
| CA (1) | CA2900912A1 (https=) |
| IL (1) | IL240440A0 (https=) |
| MX (1) | MX2015010428A (https=) |
| TW (1) | TW201444870A (https=) |
| WO (1) | WO2014125377A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140093603A (ko) | 2010-12-30 | 2014-07-28 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 병원체 불활성화제로서의 글리콜 |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| MX384222B (es) | 2013-07-05 | 2025-03-14 | Lab Francais Du Fractionnement | Matriz de cromatografia de afinidad. |
| CN106687481B (zh) * | 2014-09-10 | 2022-03-22 | 豪夫迈·罗氏有限公司 | 半乳糖改造的免疫球蛋白1抗体 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药（苏州）股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
| FR3060395B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
| US20210155710A1 (en) * | 2018-06-05 | 2021-05-27 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
| JP7273858B2 (ja) * | 2018-06-15 | 2023-05-15 | シャンハイ ミラコーケン インコーポレイティド | 癌を治療するための方法と材料 |
| CN113999313A (zh) * | 2020-07-28 | 2022-02-01 | 百奥泰生物制药股份有限公司 | 抗her2抗体及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| ES2434961T5 (es) * | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| EP2042196B1 (en) * | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| KR20080068089A (ko) * | 2005-10-21 | 2008-07-22 | 지티씨바이오쎄라퓨틱스,인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법 |
| CA2655246A1 (en) * | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
| EP2054444B1 (en) * | 2006-08-04 | 2016-11-02 | MedImmune Limited | Antibodies to erbb2 |
| SI2073842T1 (sl) * | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| CN101588817B (zh) * | 2006-09-10 | 2013-06-12 | 葛莱高托普有限公司 | 骨髓白血病来源的细胞在抗体表达中的用途 |
| EP2725035A1 (en) * | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| WO2010036443A1 (en) * | 2008-09-26 | 2010-04-01 | Eureka Therapeutics, Inc. | Cell lines and proteins with variant glycosylation pattern |
| JPWO2012105699A1 (ja) * | 2011-02-03 | 2014-07-03 | 株式会社イーベック | 補体依存性生物活性の高い抗体の産生法 |
| AU2012203048A1 (en) * | 2011-05-24 | 2012-12-13 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| EP3594231A1 (en) * | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
-
2014
- 2014-02-13 EP EP14732000.6A patent/EP2956485A2/en not_active Withdrawn
- 2014-02-13 AU AU2014217564A patent/AU2014217564B2/en not_active Ceased
- 2014-02-13 AR ARP140100460A patent/AR094781A1/es unknown
- 2014-02-13 JP JP2015557533A patent/JP2016509019A/ja active Pending
- 2014-02-13 MX MX2015010428A patent/MX2015010428A/es unknown
- 2014-02-13 CN CN201480020373.3A patent/CN105308071A/zh active Pending
- 2014-02-13 CA CA2900912A patent/CA2900912A1/en not_active Abandoned
- 2014-02-13 KR KR1020157024975A patent/KR20160003634A/ko not_active Withdrawn
- 2014-02-13 BR BR112015019343A patent/BR112015019343A2/pt not_active Application Discontinuation
- 2014-02-13 US US14/767,120 patent/US20150368357A1/en not_active Abandoned
- 2014-02-13 TW TW103104772A patent/TW201444870A/zh unknown
- 2014-02-13 WO PCT/IB2014/000711 patent/WO2014125377A2/en not_active Ceased
-
2015
- 2015-08-09 IL IL240440A patent/IL240440A0/en unknown
-
2019
- 2019-12-27 JP JP2019238917A patent/JP2020125286A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014217564B2 (en) | 2018-11-08 |
| CN105308071A (zh) | 2016-02-03 |
| AU2014217564A1 (en) | 2015-08-27 |
| WO2014125377A3 (en) | 2014-12-04 |
| JP2020125286A (ja) | 2020-08-20 |
| WO2014125377A2 (en) | 2014-08-21 |
| EP2956485A2 (en) | 2015-12-23 |
| IL240440A0 (en) | 2015-09-24 |
| AR094781A1 (es) | 2015-08-26 |
| BR112015019343A2 (pt) | 2017-08-22 |
| TW201444870A (zh) | 2014-12-01 |
| US20150368357A1 (en) | 2015-12-24 |
| KR20160003634A (ko) | 2016-01-11 |
| JP2016509019A (ja) | 2016-03-24 |
| CA2900912A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010427A (es) | Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos. | |
| MX2015010428A (es) | Anticuerpos anti-her2 altamente galactosilados y sus usos. | |
| MX2016008098A (es) | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| AU2014247175A8 (en) | Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| MY178142A (en) | Anti-phf-tau antibodies and their uses | |
| WO2013021279A3 (en) | Highly galactosylated antibodies | |
| MX2022008124A (es) | Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano. | |
| MX2019006902A (es) | Inmunoglobulinas heterodimericas. | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
| WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
| MX2015010429A (es) | Cetuximab con glicosilación modificada y sus usos. | |
| MX380754B (es) | Artículo abrasivo que incluye partículas abrasivas perfiladas. | |
| MX342034B (es) | Proteinas monovalentes que se unen a antigenos. | |
| SG10201811017QA (en) | Novel antibody frameworks | |
| MX340558B (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. | |
| MX2015011772A (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
| MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
| NZ705606A (en) | Methods for identifying antibodies with reduced immunogenicity | |
| MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
| MX366112B (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| WO2014145961A3 (en) | Hybridoma clones and monoclonal antibodies to tetraspanin 8 | |
| AR089079A1 (es) | Formulacion de anticuerpo anti-cd44 |